yttrium-90 ibritumomab tiuxetan + BEAM

Zevalin + BEAM is a combination treatment regimen used primarily for patients with relapsed or refractory non-Hodgkin's lymphoma (NHL). It combines radioimmunotherapy (Zevalin) with high-dose chemotherapy (BEAM) followed by autologous stem cell transplantation (ASCT). The BEAM component consists of: - Carmustine (BCNU): 300 mg/m² IV on day -6 - Etoposide: 200 mg/m² IV daily on days -5 to -2 - Cytarabine (Ara-C): 200 mg/m² IV twice daily on days -5 to -2 - Melphalan: 140 mg/m² IV on day -1 Zevalin (yttrium-90 ibritumomab tiuxetan) is added to this regimen, typically administered on day -14 before the BEAM chemotherapy begins. Zevalin combines immunotherapy (via the monoclonal antibody ibritumomab tiuxetan) with targeted radiotherapy (via the radioactive isotope yttrium-90). This combination delivers radiation specifically to B-cell lymphoma cells and neighboring cells. Clinical studies suggest that adding Zevalin to BEAM may improve outcomes in patients with refractory lymphoma compared to BEAM alone, with manageable toxicity profiles.

Brand names

Zevalin + BEAM

Other names

yttrium-90 ibritumomab tiuxetan-BEAMyttrium90 ibritumomab tiuxetan-BEAMyttrium 90 ibritumomab tiuxetan-BEAM90Y-ibritumomab tiuxetan-BEAMibritumomab tiuxetan-BEAM